Fig. 2: Management of Diabetic Macular Oedema (DMO)—flowchart showing treatment decision tree for DMO based on involvement of the central macula and visual acuity (VA); VEGF vascular endothelial growth factor; *Non-centred involved DMO is defined as thickened non-central macular subfields on optical coherence tomography map with either (1) at least 2 subfields with thickness above threshold or (2) at least 1 subfield with thickness of at least 15 microns above threshold [16]. | Eye

Fig. 2: Management of Diabetic Macular Oedema (DMO)—flowchart showing treatment decision tree for DMO based on involvement of the central macula and visual acuity (VA); VEGF vascular endothelial growth factor; *Non-centred involved DMO is defined as thickened non-central macular subfields on optical coherence tomography map with either (1) at least 2 subfields with thickness above threshold or (2) at least 1 subfield with thickness of at least 15 microns above threshold [16].

From: Management of diabetic macular oedema: new insights and global implications of DRCR protocol V

Fig. 2: Management of Diabetic Macular Oedema (DMO)—flowchart showing treatment decision tree for DMO based on involvement of the central macula and visual acuity (VA); VEGF vascular endothelial growth factor; *Non-centred involved DMO is defined as thickened non-central macular subfields on optical coherence tomography map with either (1) at least 2 subfields with thickness above threshold or (2) at least 1 subfield with thickness of at least 15 microns above threshold [16].The alternative text for this image may have been generated using AI.

CRT central retinal thickness.

Back to article page